MedTech News
New bone marrow imaging technique could pave way for drug development and new therapies
Indiana University School of Medicine scientists have developed a powerful new imaging technique to study bone marrow in mouse models. By overcoming key challenges unique to imaging this complex tissue, this advancement could support future drug development and therapies for conditions involving bone marrow, including cancers, autoimmune diseases and musculoskeletal disorders.
Potential new treatment for uncontrolled hypertension results in a 15-point reduction in systolic number
Researchers at the University of California San Diego School of Medicine have identified a potential new treatment, an investigational drug called lorundrostat, for individuals with uncontrolled or treatment-resistant hypertension, commonly known as high blood pressure.
Metabolic driver of Parkinson’s disease offers new target for treatment
Researchers have identified a key enzyme driving forms of Parkinson’s disease, and have shown how blocking it restores normal function in animal and cell models, offering a promising new drug target for the condition.
BD Launches First-of-its-Kind Bioabsorbable Mesh for Umbilical Hernia Repair
Innovative mesh aims to improve patient outcomes by naturally absorbing into the body post-surgery.
Xtant Medical Unveils Trivium™ Advanced Bone Graft
Designed to optimize bone regeneration, the new graft technology promises superior clinical outcomes in spinal and orthopedic procedures.
CereVasc’s eShunt® System Receives FDA Breakthrough Device Designation for Pediatric Use
Innovative endovascular treatment for communicating hydrocephalus gains regulatory support for patients aged 12 and older.
Baebies Receives FDA Breakthrough Device Designation for First Point-of-Care Heparin Monitoring Test
DURHAM, N.C., April 23, 2025 /PRNewswire/ — Baebies has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Anti-Factor Xa test on the FINDER® platform —the first point-of-care heparin monitoring assay. Designed for patients receiving unfractionated or low molecular weight heparin, the test provides results in under 15 minutes from just 50 µL of whole blood. This designation recognizes the test’s potential to bring heparin monitoring closer to the patient, enabling faster and more effective dose management in critical care settings.
CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry
SEOUL, South Korea, April 23, 2025 /PRNewswire/ — CGBIO(CEO Hyun Seung Yu), a leading Korean company specializing in bio-regenerative medicine, proudly announces that its innovative bone graft substitute, NOVOSIS PUTTY, has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). This pivotal approval paves the way for a clinical trial in spinal fusion procedures within the United States.